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Abstract Ayurveda is a renowned traditional medicine practiced in India from ancient times and Clitoria ternatea is one
such prospective medicinal herb incorporated as an essential constituent in a brain tonic called as medhya rasayan for
treating neurological disorders. This work emphasises the significance of the plant as a brain drug there by upholding
Indian medicine. The phytochemicals from the root extract were extricated using gas chromatography–mass spectrometry
assay and molecular docking against the protein Monoamine oxidase was performed with four potential compounds along
with four reference compounds of the plant. This persuades the prospect of C. ternatea as a remedy for neurodegenerative
diseases and depression. The in silico assay enumerates that a major compound (Z)-9,17-octadecadienal obtained from the
chromatogram with a elevated retention time of 32.99 furnished a minimum binding affinity energy value of -6.5 kcal/mol
against monoamine oxidase (MAO-A). The interactions with the amino acid residues ALA 68, TYR 60 and TYR 69 were
analogous to the reference compound kaempferol-3-monoglucoside with a least score of -13.90/-12.95 kcal/mol against
the isoforms (MAO) A and B. This study fortifies the phytocompounds of C. ternatea as MAO-inhibitors and to acquire a
pharmaceutical approach in rejuvenating Ayurvedic medicine.
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1 Introduction
Alternative medicines disburse a new stratagem in restor-
ing health and traditional medicines like Ayurveda has an
embedded background and its patrons are drawn from
ancient communities. The antiquity seized by ayurvedic
medicine has formulated treatises to enhance mental health
that promote memory and intelligence [1]. Medhya drugs
constitute an assemblage of medicinal herbs that acts on the
nervous system and improve mental abilities [2]. Medhya
rasayana is a brain and nervine tonic that has been used for
centuries in rejuvenating neurons and treating neurological
diseases [3, 4]. Shankhpushpi is a reputed drug constituted
in medhya rasayana whose name is derived from Sanskrit
language. It illustrates a plant with flowers shaped like a
conch or shankha which is a sacred instrument used in
ritual worships. According to the pharmacopoeia of India,
Convolvulus pluricaulis (Convolvulaceae) as a whole plant
rightfully claim the name of Shankapushpi but, Ayurvedic
practitioners have used three other medicinal herbs such as
Evolvulus alsinoides Linn. (Convolvulaceae), Canscora
decussata Schult. (Gentianaceae) and Clitoria ternatea
Linn. (Papilionaceae) [5–9].
Though all the four plants are catalogued under the same
class Magnoliopsida, C. ternatea separates itself at the
level of sub-class belonging to Rosidae, while the other
three belong to Asteridae. Clitoria ternatea, is distinct
among other herbs and has the property of being a good
brain drug [10]. Therefore there is a sturdy instinct to
evaluate the phytoconstituents of the plant to treat mental
disorders. A wide range of phytocompounds including
ternatins, alkaloids, flavonoids, saponins, tannins, carbo-
hydrates, proteins, resins, starch, taraxerol, taraxerone and
secondary metabolites such as triterpenoids, flavonol gly-
cosides, anthocyanins, steroid elevates the hope of
endorsing C. ternatea as an efficient botanical medicine
combating neurological ailments. This study exonerates the
phytocompounds present in the root extract of the plant
with a gas chromatography–mass spectrometry assay pur-
sued by a molecular docking against a flavoenzyme
Monoamine oxidase (MAO).
This protein is responsible for the oxidative deamination
of neurotransmitter and dietary amines [11–13]. This
enzyme degrades neurotransmitters such as serotonin and
dopamine in the brain which is coded for by the MAOA
gene [14–16]. Neurotransmitters play a pivotal role in
mood, arousal, and emotions, even affecting impulse
control.
The isoforms of Monoamine Oxidase (A and B) are
categorised based on their substrate preference and inhi-
bitor selectivity. Inhibitors of MAO-A are clinically used
as antidepressants and anxiolytics [17, 18] while MAO-B
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inhibitors are used for the treatment of Parkinson’s dis-
ease and for symptoms associated with Alzheimer’s dis-
ease [19, 20].
Although several synthetic monoamine oxidase inhibitor
(MAOI) have emerged as antidepressant drugs, the desire
of herbal medicine is excessive. They are proficient in
surpassing the adverse effects and improves a better sus-
tainability. Hence a substantial study establishing C. ter-
natea as monoamine oxidase inhibitor (MOAI) fetches a
stoppage solution against depression and neurological
problems which hoists Ayurveda extensively.
2 Results and Discussion
Phytochemical assay of the plant C. ternatea was per-
formed to divulge the essential phytocompounds which
draw a base line in accessing their medicinal significance.
The roots of the plant have an extended antiquity to pro-
mote mental power memory retention and alleviate psy-
chotic stress [21]. Studies have revealed that aqueous root
extract of C. ternatea enhances memory in rats while,
alcoholic extracts of aerial and root parts of C. ternatea
attenuated electroshock-induced amnesia [22, 23]. Hence
this study determined root as the vital part that reveals the
utmost essential phytocompounds.
2.1 Extraction of Volatile Phytochemicals Augmenting
Brain Function by GC–MS Assay
GC–MS chromatogram analysis pertained from the ethanol
extract ofC. ternatea (Fig. 1) extricated twenty-five different
compounds illustrated with twenty intense peaks indicating
the presence of these phytochemical in a high constituent.
The phytocompounds were detected and catalogued in
parallel to the NIST library (Table 1). Among them, themost
prevailing compounds are n-hexadecanoic acid (21.32 %)
and (Z)-9,17-Octadecadienal (28.76 %), with a retention
time of 22.62 and 26.73 min. D-Allose (17.53 %), pyr-
rolo[1,2-a]pyrazine-1,4-dione (5.5 %), and 2,3-dihydro-3,5-
dihydroxy-6-methyl-4H-pyran-4-one (3.76 %) pursue the
former compounds with a retention time of 16.83, 23.13
and 9.91 min. The foremost compound (Z)-9,17-octadeca-
dienal is categorized as aldehyde and commonly called as
linolenic acid. It is an essential omega-3 fatty acid that has an
explicit therapeutic value in regulating cholesterol level in
blood. Reports unveil that they have neuroprotective prop-
erties and increased intake of a-linolenic acid reduced
depressive symptoms thereby maintaining robust mental
health mental health [24–26]. Furthermore, palmitic acid
(n-hexadecanoic acid) is one another indigenous compound
which has an antioxidant property and acts as a 5-alpha
reductase inhibitor [27]. Studies report that it has anticon-
vulsant and antidepressant property. The scavenging and
inhibition of free radicals, inhibits the neurotoxicity of
amyloid-b thereby offering protection against hypoxic chal-
lenges [28–30]. A diverse range of flavonoids occurs in tra-
ditional medicine that exert as sedatives and carry out
anxiolytic effects. This is due to the cognitive enhancement of
the up regulation of cholinergic that results in the binding of
GABAA receptors [29, 30]. This results in the inhibition of
monoamine oxidase thereby raising the level of noradrenalin
[31]. 2,3-Dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one
is characterized as a fragment of flavanoids which when
synthesised by plants, are termed as phytoestrogens. Epi-
demiological studies suggests that they have the potentials of
treating neurologic disorders such as dementia and Alzhei-
mer’s disease [32, 33]. Hence the analysis of GC–MS further
extends a need of study to assay the antidepressant and neu-
roprotective aspect of the major compounds extricated from
the root extract.







































Fig. 1 A chromatogram illustrating the presence of bioactive phytochemicals
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Table 1 List of extricated compounds attained from GC–MS Assay
S. no. Peak name Retention time Peak area % Peak area
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2.2 Molecular Docking Studies
An in silico assay was done to determine the best com-
pound by docking against the depression and neurode-
generative inducing protein MOA (Mono Amine Oxidase).
Alterations in monoaminergic transmission are reported to
be related with the instigation of neurodegenerative dis-
eases such as Parkinson’s, Alzheimer’s diseases and psy-
chiatric disorders such as depression and anxiety [34]. In
the present study, four phytocompounds confiscated from
the root extracts of C. ternatea were docked computa-
tionally into the active site of the monoamine oxidase
isoforms (MAO-A and MAO-B) and were investigated to
endorse their inhibitory potency. Former studies deem to
have the presence of imperative primary and secondary
metabolites from the whole plant that are medically sig-
nificant. Combined chemical analysis have isolated many
vital phytocompounds such as kaempferol (kaempferol
3-neohesperidoside, kaempferol 3-rutinoside, kaempferol
3-glucoside), quercetin (quercetin 3-2 G-rhamnosyl ruti-
noside, quercetin 3-neohesperidoside, Quercetin 3-ruti-
noside, quercetin 3-glucoside), Myricetin 3-neohes-
peridoside, Myricetin 3-rutinoside, Myricetin 3-glucoside
and delphinidin 3,3,5-triglucoside [35–38]. Conversely,
there is a need of a study to explicit these phytocompounds
against a target as obstacle. Hence four reference
Table 1 continued
S. no. Peak name Retention time Peak area % Peak area
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compounds (kaempferol-3-monoglucoside, Delphinidin-
3,5-diglucoside, Malvidin-3-O-glucoside and Quercetin)
were elected to endure docking studies, comparable with
four experimented phytochemicals such as (Z)-9,17-
octadecadienal, 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-
pyran-4-one, n-decanoic acid and n-hexadecanoic acid.
These compounds were preferred by considering their
retention time and medicinal assets. The phytocompounds
had the potential to dock with the target proteins and their
interaction details are listed in Table 2 and illustrated in
Fig. 2. The target protein Monoamine oxidase (MAO) A
was counteracted by three and (MAO) B with two
reference compounds (Fig. 3), where kaempferol-3-
monoglucoside exhibited with a least score of -13.90/
-12.95 kcal/mol. Binding studies was competitive among
all the four test compounds the major compound (Z)-9,17-
octadecadienal obtained from the gas chromatogram assay
with a high retention time (32.99) exhibited a minimum
Table 2 Hit list of the ligands with the target protein MAO-A

















































Pub Chem ID: 10100906
– – – –
5. Name: 9,17 Octadecadienal,(Z)-
Formula: C18H32O
MW: 264









Pub Chem ID: 119838
-6.21223 1 1.72 PHE208
7. Name: n-Hexadecanoic acid
Formula: C16H32O2
MW: 256







8. Name: n-Decanoic acid
Formula: C10H20O2
MW: 172
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Fig. 2 a Interaction between
kaempferol-3-monoglucoside
and Mono Amine Oxidase A
conducted by the amino acid
residues ALA68, GLN443,
GLY66, MET445, TYR69 and
ASN181. b Interaction between
Quercetin and Mono Amine
Oxidase A conducted by the
amino acid residues ASN181
and PHE 208. c Interaction
between Malvidin-3-0-
glucoside and Mono Amine
Oxidase A conducted by the
amino acid residues ALA68,
TYR69 and GLN215.
d Interaction between (Z)-9,17-
octadecadienal and monoamine
oxidase A conducted by the




one and monoamine oxidase A
conducted by the amino acid
residue PHE 208. f Interaction
between n-hexadecanoic acid
and monoamine oxidase A
conducted by the amino acid
residues ALA68 and MET 445.
g Interaction between
n-decanoic acid and monoamine
oxidase A conducted by the
amino acid residues ALA68,
MET 445 and TYR69
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binding affinity energy values of -6.5/-7.71 kcal/mol
against both the isoforms of monoamine oxidase (MAO)
A and B. n-Hexadecanoic acid commonly known as
palmitic acid conferred resistant against monoamine oxi-
dase (MAO) B as depicted in Fig. 3c with a least docking
score of -10.5001 kcal/mol. The active site associated
with both the isoforms of monoamine oxidase is com-
posed of amino acid residues, such as TYR 69, TYR 197,
PHE 208, GLU 216, TYR 407, PHE 352, TYR 444
(MAO) A and PHE 103, PRO 104, TRP 119, LEU 167,
PHE 168, LEU 171, ILE 199, ILE 316 and TYR 326
(MAO) B [34, 39, 40]. The phytocompounds quercetin
and 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one
interacted with the active site of (MAO) A with the amino
acid residue PHE 208. The study investigated diversity in
the amino acid residues distinct from the active sites of
both MAO A (ALA 68, GLN 443, GLN 66, MET 445,
TYR 69 and ASN 181) and MAO B (LYS 296, TYR 60,
GLY 434, MET 486, ILE 197, TYR 435 and CYS 172)
(Table 3).
3 Conclusion
The present study provides an evidence for the extricated
phytocompounds from the plant C. ternatea as new potent
and selective hMAO-inhibitors. The results hoists two
compounds, (Z)-9,17-octadecadienal and n-hexadecanoic
Fig. 2 continued
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Fig. 3 a Interaction between
kaempferol-3-monoglucoside
and monoamine oxidase B
conducted by the amino acid
residues LYS296, TYR60 and
GLN434. b Interaction between
quercetin and monoamine
oxidase B conducted by the




conducted by the amino acid
residueTYR 60. d Interaction
between (Z)-9,17-
octadecadienal and monoamine
oxidase B conducted by the
amino acid residue MET 436.




conducted by the amino acid
residue TYR 435 and ILE 198.
f Interaction between
n-decanoic acid and monoamine
oxidase B conducted by the
amino acid residue CYS 172
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acid as potential lead molecules for developing novel
selective MAO-A inhibitors which can confer herbal rem-
edy in the treatment of psychiatric disorders such as
depression, anxiety, and also cognitive impairments in
Alzheimer’s and Parkinson’s Diseases. The in silico assay
endorses the reference phyto compound Kaempferol–
monoglucoside as an established brain drug. Further the
study commences amino acid residues which are distinct
from the residues pertaining to the active sites of mono-
amine Oxidase A and B. The efficacy of these potent phy-
tocompounds can be further elucidated with clinical studies.
4 Experimental Section
4.1 Chemicals
All chemicals used were of analytical grade purchased
from, sigma Aldrich Ltd.
4.2 Plant Collection and Identification
The healthy plant samples were collected from the pre-
mises of Bishop Heber College, Tiruchirappalli, India. The
Fig. 3 continued
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roots from the whole plant was segregated, cleaned and
allowed to dry under the shade. The identification and
voucher specimen number AAM 001 of the plant was
sorted out and deposited at the Rapinat Herbarium and
Centre for Molecular Systematic (St. Joseph’s, College
Tiruchirappalli, India). The authentication of the plant as
C. ternatea L. was validated by Dr. S. John Britto
(Director).
4.3 Preparation of Plant Extract
The shade dried powdered root sample (100 gm) was
extracted with 250 mL of ethanol in a Soxhlet apparatus
for 72 h. The plant extract yielded was filtered and evap-
orated to dryness which was further used for analysis.
4.4 Gas Chromatography–Mass Spectrometry Analysis
GC–MS analysis of the plant extract was performed using a
Perkin–Elmer Clarus 500 system comprising an AOC-20i
auto-sampler. The Gas Chromatograph is interfaced to a
Mass Spectrometer (GC–MS) equipped with a column (Id:
250 lm,) Elite-5MS (5 % diphenyl/95 % dimethyl poly
siloxane) fused extended to a length of (30 m). For GC–
MS detection, an electron ionization system was operated
in electron impact mode with ionization energy of 70 eV.
Table 3 Hit list of the ligands with the target protein MAO-B
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Pub Chem ID: 10100906
– – – –
5. Name: n-Hexadecanoic acid
Formula: C16H32O2
MW: 256
Pub Chem ID: 985
-10.5001 1 2.43 TYR 60
6. Name: 9,17 Octadecadienal,(Z)-
Formula: C18H32O
MW: 264
Pub Chem ID: 5365667
-7.71444 1 2.01 MET 436









8. Name: n-Decanoic acid
Formula: C10H20O2
MW: 172
Pub Chem ID: 2969
-4.29637 1 1.85 CYS 172
A Strategy to Employ Clitoria ternatea Against Neurodegenerative Diseases and Depression 303
123
a  





Fig. 4 3 D Structures of the phytochemicals as ligands. a kaempferol-
3-monoglucoside (CID: 5282102). b Delphinidin-3,5-diglucoside
(CID:10100906). c Malvidin-3-0-glucoside(CID: 443652). d Quercetin
(CID: 5280343). e d.9,17-Octadecadienal, (Z)- (CID: 5365667). f.
4H-Pyran-4-one, 2,3-dihydro-3,5-dihydroxy-6-methyl (CID:119838).
g n-Decanoic acid (CID: 2969). h n-Hexadecanoic acid (CID: 985)
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Helium gas (99.999 %) was used as a carrier gas at a con-
stant flow rate of 1 ml/min, and a sample injection volume
of 1.6 ll was employed (a split ratio of 10:1). The injector
temperature was maintained at 280 C, the ion-source tem-
perature was 200 C, the oven temperature was programmed
from 60 C (isothermal for 8 min) which, increased to
200 C, for 5 min at 7 C to 280 C, ending with 280 C
(isothermal) for 15 min. Mass spectra were taken at 70 eV at
a scan interval of 0.5 s and fragments from 45 to 450 Da.
The relative percentage amount of each component was
calculated by comparing its average peak area to the total
areas. The mass-detector used in this analysis was Turbo-
Mass Gold-Perkin-Elmer, with the software Turbo-Mass
ver-5.2 to handle the mass spectra and chromatograms.
4.5 Identification of Phytocomponents
Interpretation on mass-spectrum GC–MS was conducted
using the database of National Institute Standard and
Technology (NIST) having more than 62000 patterns. The
spectrum of the unknown components was compared with
the spectrum of known components stored in the NIST
library. The name, molecular weight, and structure of the
components of the test materials were ascertained.
4.6 Docking Analysis
Molecular docking studies were carried to identify the
binding affinities and interaction between the inhibitors and
the target proteins (Mono Amine Oxidase) MAO-A and
MAO-B using Glide software (Schrodinger Inc. U.S.A.-
Maestro version 10.2). Grid-based Ligand Docking with
Energetic (Glide) is one of the most accurate docking tool
available for ligand–protein, protein–protein binding stud-
ies. Glide was found to produce least number of inaccurate
poses and 85 % of Glides binding models had an RMSD of
1.4 A or less from native co-crystallized structures.
4.7 Preparation of Ligands
The 3-dimensional structures of the phytocompounds
considered as ligands were retrieved and downloaded
(Fig. 4a–h) as mol files from the site of Pub Chem. The
molecules were processed using the LigPrep tool from
Schrodinger to obtain the perfect conformation by the
addition or removal of hydrogen atoms with respect to the
OPLS_2005 force field.
4.8 Preparation of Protein Target
The target proteins Mono Amine Oxidase MAO-A and
MAO-B were retrieved from Protein Data Bank (PDB).
Water molecules were removed and a single chain was
selected between two chains. Generally, all waters (except
those coordinated to metals) are deleted, but water that
connects between the ligand and the protein are sometimes
retained. Problems in the PDB protein structure were
repaired by adjusting the protein, metal ions, and cofactors.
The structure forming bonds from the ligand or a cofactor
to a protein metal were deleted by adjusting the ligand
bond orders and formal charges. The minimization was
done to restrain the input protein coordinates by a selected
RMSD tolerance.
4.9 GLIDE/Ligand Docking
Grid generated output file was uploaded as an input for
Ligand docking against protein prepared targets in GLIDE.
SP (Standard Precision) mode was adopted. Flexible
docking mode was selected.
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